$PM

Trump’s Surgeon General Pick Loves These 3 Tobacco Stocks

Philip Morris (PM) has a consensus 'Moderate Buy' rating with a $206.43 price target, implying 6% upside. Altria Group (MO) gained 22% YTD, with a $69.58 consensus target. British American Tobacco (BTI) has a 22% upside target amid restructuring and smokeless product growth.

Original reporting
Published Sep 17, 2026, 6:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 7:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Trump’s Surgeon General Pick Loves These 3 Tobacco Stocks — source image
Decision brief

The 30-second read

$PMBullishLow
01

Why it matters

No new earnings or regulatory events; the piece is a summary of existing analyst opinions.

02

Market read

Analyst target revisions provide modest guidance but lack a fresh catalyst, limiting trading relevance.

03

What to watch

Regulatory pressures and litigation risks could offset any upside.

Relevance 4/10Novelty 2/10Timing: none

Background

The article compiles recent analyst price targets and a new contract between Altria and Philip Morris.

Company-level read

Ticker impact

$PMBullishMedium confidence
Context

Analysts raise Philip Morris price target to $206.43, indicating a 6% upside.

Expected impact

Potential modest price appreciation if targets are incorporated.

Evidence & confidence

Consensus rating remains Moderate Buy; price target increase is modest and not a catalyst.

$MONeutralLow confidence
Context

Altria reports a contract with Philip Morris and a consensus price target of $69.58.

Expected impact

Limited impact; market already priced in modest upside.

Evidence & confidence

Agreement is minor and price targets show little change from current levels.

$BTIBullishMedium confidence
Context

British American Tobacco receives a consensus price target of $68.28, 22% above current price.

Expected impact

Potential upside if market re‑rates the stock.

Evidence & confidence

Target increase is notable but lacks a fresh catalyst beyond analyst sentiment.

Market effects

Tobacco sector may see modest re‑rating as analysts lift targets.

U.S. and UK tobacco stocks could see slight buying pressure.

Limited; impact confined to tobacco equities.

Counterpoint

Targets may be overly optimistic given structural decline in cigarette volumes.

Key entities

  • Philip Morris International

    Tobacco company with updated analyst price target.

  • Altria Group

    U.S. tobacco firm with a new contract and price target.

  • British American Tobacco

    Global tobacco firm with raised analyst price target.

Related articles

$BTIMed

BAT Sees Nicotine Pouches Driving Growth In Smoking Alternatives

British American Tobacco (BAT) anticipates mid-teens annual revenue growth from smoking alternatives until 2030, driven by nicotine pouches, with industry revenues expected to grow 4% from 2025-2030. BAT predicts nicotine pouch revenues will triple, with a 30% contribution margin by 2030. The company also expects global tobacco volumes to decline 2.5% in the same period and remains on track to meet its 2026 financial guidance.

$BTIMed

British American Tobacco (BTI) Outlines Growth Targets at Capita

British American Tobacco (BTI) outlined growth targets at its Capital Markets Day, aiming for mid-teens revenue growth in new product categories by 2030. The company projects 3-5% revenue growth for 2026 and maintains a 5.93% dividend yield with a 41% payout ratio. BTI's shares are currently 34.1% overvalued according to GuruFocus' GF Value™ estimate.

$BTIHighAI 8/10

BAT stock falls after cutting 2026 growth outlook

British American Tobacco (BATS) shares dropped 1.7% after the company revised its 2026 growth outlook, expecting lower-end revenue (3-5%) and profit (4-6%) growth, and mid-range EPS growth (5-8%). The company also outlined its 2030 ambitions, aiming for mid-teens New Category revenue growth and a 30% contribution margin. BATS expects a 2-2.5% FX headwind on 2026 EPS growth.

$BTIMed

FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions

The FDA updated Import Alert 98-07 to include its May 2026 enforcement policy for unauthorized ENDS, affecting import detention procedures. The policy prioritizes enforcement based on product risk and application status. Examples include Charlie's Holdings' PACHA and R.J. Reynolds' Vuse Pro, neither of which gained marketing authorization. The revision maintains DWPE but adds Center for Tobacco Products review for certain cases.

$MOMed

Trump administration plans to speed approvals of vapes and nicotine pouches - WSJ

The Trump administration plans to speed up approvals for smoke-free nicotine products like vapes and nicotine pouches, easing FDA review requirements. This benefits tobacco companies such as Altria (MO), Philip Morris (PM), and British American Tobacco (BTI), which face regulatory delays. The move aims to reduce illegal products but faces opposition from health advocates concerned about youth access.